De Novo Ventures, established in 2000 and based in Saratoga, California, is a private equity firm specializing in venture capital investments within the healthcare and biotechnology sectors. With $650 million under management, the firm has made over 40 investments across three funds, focusing on both early-stage and late-stage companies. De Novo Ventures was founded by experienced investors and medical device entrepreneurs who aimed to leverage their extensive backgrounds to support and guide emerging businesses. Their unique expertise allows them to provide valuable advice to entrepreneurs and management teams throughout the entire lifecycle of a company, fostering significant clinical impact and strong financial returns.
Milo is a group action communicator, sophisticated wireless networking, audio processing & powerful hardware in a carefully crafted design.
Avedro
Series F in 2018
Avedro, Inc. is a medical device and pharmaceutical company specializing in the treatment of corneal disorders, particularly corneal ectatic conditions and refractive errors. The company has developed the Avedro Corneal Remodeling platform, which includes the KXL and Mosaic systems that utilize ultraviolet A (UVA) light, alongside a range of single-use riboflavin drug formulations. These technologies are primarily aimed at treating progressive keratoconus and corneal ectasia following refractive surgery. Avedro also focuses on advancing the science of Thermo-biomechanics, exemplified by its Keraflex procedure, a non-invasive method for corneal reshaping that preserves the cornea's biomechanical integrity. The company's products are marketed to ophthalmologists, hospitals, and ambulatory surgery centers in the United States and through international distributors. Avedro, originally established as ThermalVision, Inc. in 2002, is headquartered in Waltham, Massachusetts, and operates as a subsidiary of Glaukos Corporation.
Avedro
Venture Round in 2017
Avedro, Inc. is a medical device and pharmaceutical company specializing in the treatment of corneal disorders, particularly corneal ectatic conditions and refractive errors. The company has developed the Avedro Corneal Remodeling platform, which includes the KXL and Mosaic systems that utilize ultraviolet A (UVA) light, alongside a range of single-use riboflavin drug formulations. These technologies are primarily aimed at treating progressive keratoconus and corneal ectasia following refractive surgery. Avedro also focuses on advancing the science of Thermo-biomechanics, exemplified by its Keraflex procedure, a non-invasive method for corneal reshaping that preserves the cornea's biomechanical integrity. The company's products are marketed to ophthalmologists, hospitals, and ambulatory surgery centers in the United States and through international distributors. Avedro, originally established as ThermalVision, Inc. in 2002, is headquartered in Waltham, Massachusetts, and operates as a subsidiary of Glaukos Corporation.
TearScience
Series D in 2016
TearScience, Inc. is a medical device company based in Morrisville, North Carolina, focused on the identification, diagnosis, and treatment of Meibomian Gland Dysfunction (MGD), which is the primary cause of evaporative dry eye affecting over 100 million people globally. The company has developed innovative devices such as the LipiFlow Activator, which delivers automated therapeutic energies to meibomian glands while safeguarding the eye's delicate structures, and LipiScan, an imaging system that allows eye care professionals to assess gland health. MGD is often under-recognized and contributes significantly to dry eye symptoms such as irritation, dryness, and visual disturbances. By providing a comprehensive in-office system, TearScience enables eye care professionals to effectively address the root causes of evaporative dry eye, ultimately improving patient outcomes. The company, originally known as Kolis Scientific, Inc., was rebranded in 2005 and is now a subsidiary of Johnson & Johnson Surgical Vision, Inc.
Benvenue Medical
Series F in 2016
Benvenue Medical, Inc. is a company specializing in the design, manufacture, and marketing of minimally invasive expandable implant systems for the treatment of spinal disorders, particularly vertebral compression fractures and degenerative disc diseases. Its key products include the Kiva treatment system, which addresses spinal fractures in the thoracic and lumbar regions, and the Blazer – C system, designed for pathological vertebral compression fractures. Additionally, the company offers the Luna 3D expandable interbody fusion system, suitable for various surgical approaches. Headquartered in Santa Clara, California, Benvenue Medical serves customers across the United States, Canada, Belgium, France, and Germany. Founded in 2004, the company is committed to providing innovative solutions that enhance patient outcomes and restore spinal alignment.
Benvenue Medical
Series E in 2014
Benvenue Medical, Inc. is a company specializing in the design, manufacture, and marketing of minimally invasive expandable implant systems for the treatment of spinal disorders, particularly vertebral compression fractures and degenerative disc diseases. Its key products include the Kiva treatment system, which addresses spinal fractures in the thoracic and lumbar regions, and the Blazer – C system, designed for pathological vertebral compression fractures. Additionally, the company offers the Luna 3D expandable interbody fusion system, suitable for various surgical approaches. Headquartered in Santa Clara, California, Benvenue Medical serves customers across the United States, Canada, Belgium, France, and Germany. Founded in 2004, the company is committed to providing innovative solutions that enhance patient outcomes and restore spinal alignment.
Spinal Kinetics
Venture Round in 2014
Spinal Kinetics LLC is a medical device company based in Sunnyvale, California, dedicated to developing non-fusion motion preservation systems for treating degenerative diseases of the spine. Founded in 2003, the company offers two primary products: the M6-C artificial cervical disc and the M6-L artificial lumbar disc, both designed to replicate the anatomical and biomechanical characteristics of natural intervertebral discs. These innovations provide options for artificial disc replacement in the cervical and lumbar regions. Spinal Kinetics collaborates with spine surgeons to ensure that its products meet clinical needs and are sold through a network of distributors across various countries, including Australia, Germany, the United Kingdom, and the United Arab Emirates. The company operates as a subsidiary of Orthofix Medical Inc.
EndoGastric Solutions
Series G in 2014
EndoGastric Solutions, Inc. is a medical device company specializing in innovative surgical technologies aimed at treating gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, the company develops and manufactures natural orifice surgical products. Its flagship technology, EsophyX, facilitates transoral reconstructive surgery, while the EsophyX Z device is specifically designed for the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions offers SerosaFuse Fasteners, a non-resorbable polypropylene product that provides strength comparable to traditional sutures. The company also supports surgeons through training courses and a range of consultative services, including pre-authorization and medical review.
MyoScience
Series E in 2013
MyoScience Inc., founded in 2005 and based in Redwood City, California, focuses on the development and commercialization of innovative dermatological products. The company leverages advanced technology to create solutions aimed at addressing various skin-related issues. Through its efforts, MyoScience aims to provide effective products that enhance skin health and appearance.
Tria Beauty
Private Equity Round in 2013
TRIA Beauty, Inc. specializes in developing and selling light-based medical devices designed for consumer use in skincare and beauty treatments. The company's primary offerings include a hand-held diode laser device for permanent hair removal, a Skin Perfecting Blue Light device targeting acne-causing bacteria, a Skin Rejuvenating Laser for anti-aging, and an Age-Defying Eye Wrinkle Correcting Laser aimed at reducing fine lines around the eyes. These products leverage advanced light technology, typically used in professional dermatological treatments, allowing users to achieve salon-quality results at home. TRIA Beauty markets its products through its e-commerce platform and various indirect sales channels, including television, retail locations, and physician offices. Founded in 2003 and headquartered in Dublin, California, TRIA Beauty serves customers across multiple countries, including the United States, Japan, and several European nations. The company previously operated under the name SpectraGenics, Inc. before rebranding in 2008.
Avedro
Series D in 2013
Avedro, Inc. is a medical device and pharmaceutical company specializing in the treatment of corneal disorders, particularly corneal ectatic conditions and refractive errors. The company has developed the Avedro Corneal Remodeling platform, which includes the KXL and Mosaic systems that utilize ultraviolet A (UVA) light, alongside a range of single-use riboflavin drug formulations. These technologies are primarily aimed at treating progressive keratoconus and corneal ectasia following refractive surgery. Avedro also focuses on advancing the science of Thermo-biomechanics, exemplified by its Keraflex procedure, a non-invasive method for corneal reshaping that preserves the cornea's biomechanical integrity. The company's products are marketed to ophthalmologists, hospitals, and ambulatory surgery centers in the United States and through international distributors. Avedro, originally established as ThermalVision, Inc. in 2002, is headquartered in Waltham, Massachusetts, and operates as a subsidiary of Glaukos Corporation.
Tria Beauty
Venture Round in 2012
TRIA Beauty, Inc. specializes in developing and selling light-based medical devices designed for consumer use in skincare and beauty treatments. The company's primary offerings include a hand-held diode laser device for permanent hair removal, a Skin Perfecting Blue Light device targeting acne-causing bacteria, a Skin Rejuvenating Laser for anti-aging, and an Age-Defying Eye Wrinkle Correcting Laser aimed at reducing fine lines around the eyes. These products leverage advanced light technology, typically used in professional dermatological treatments, allowing users to achieve salon-quality results at home. TRIA Beauty markets its products through its e-commerce platform and various indirect sales channels, including television, retail locations, and physician offices. Founded in 2003 and headquartered in Dublin, California, TRIA Beauty serves customers across multiple countries, including the United States, Japan, and several European nations. The company previously operated under the name SpectraGenics, Inc. before rebranding in 2008.
Benvenue Medical
Series D in 2012
Benvenue Medical, Inc. is a company specializing in the design, manufacture, and marketing of minimally invasive expandable implant systems for the treatment of spinal disorders, particularly vertebral compression fractures and degenerative disc diseases. Its key products include the Kiva treatment system, which addresses spinal fractures in the thoracic and lumbar regions, and the Blazer – C system, designed for pathological vertebral compression fractures. Additionally, the company offers the Luna 3D expandable interbody fusion system, suitable for various surgical approaches. Headquartered in Santa Clara, California, Benvenue Medical serves customers across the United States, Canada, Belgium, France, and Germany. Founded in 2004, the company is committed to providing innovative solutions that enhance patient outcomes and restore spinal alignment.
EndoGastric Solutions
Venture Round in 2012
EndoGastric Solutions, Inc. is a medical device company specializing in innovative surgical technologies aimed at treating gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, the company develops and manufactures natural orifice surgical products. Its flagship technology, EsophyX, facilitates transoral reconstructive surgery, while the EsophyX Z device is specifically designed for the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions offers SerosaFuse Fasteners, a non-resorbable polypropylene product that provides strength comparable to traditional sutures. The company also supports surgeons through training courses and a range of consultative services, including pre-authorization and medical review.
Astute Medical
Series C in 2012
Astute Medical, Inc. is a life science tools company specializing in the discovery and development of protein biomarkers for rapid diagnosis and risk assessment of acute medical conditions. Founded in 2007 and based in San Diego, California, with a location in Paris, France, the company focuses on validating prognostic biomarkers related to conditions such as abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury, and sepsis. Its primary product, NephroCheck, is a single-use cartridge designed to detect biomarkers of acute kidney injury, while the Astute140 meter converts the fluorescent signals from the NephroCheck cartridge into a single numerical result. Astute Medical's products are marketed in the United States and Europe and aim to enhance clinical decision-making and patient outcomes. As of April 2018, Astute Medical operates as a subsidiary of bioMérieux S.A.
WaveTec Vision
Venture Round in 2012
WaveTec Vision, founded in 1997 and located in Aliso Viejo, California, specializes in advanced wavefront measurement technology for cataract surgery. The company's proprietary intraoperative aberrometer system, ORange, allows surgeons to measure the eye and enhance surgical outcomes in real-time. By facilitating the convergence of refractive and cataract surgery, WaveTec Vision aims to improve the overall efficacy and precision of these procedures, ultimately benefiting patient care and satisfaction.
EndoGastric Solutions
Venture Round in 2012
EndoGastric Solutions, Inc. is a medical device company specializing in innovative surgical technologies aimed at treating gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, the company develops and manufactures natural orifice surgical products. Its flagship technology, EsophyX, facilitates transoral reconstructive surgery, while the EsophyX Z device is specifically designed for the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions offers SerosaFuse Fasteners, a non-resorbable polypropylene product that provides strength comparable to traditional sutures. The company also supports surgeons through training courses and a range of consultative services, including pre-authorization and medical review.
MyoScience
Series D in 2012
MyoScience Inc., founded in 2005 and based in Redwood City, California, focuses on the development and commercialization of innovative dermatological products. The company leverages advanced technology to create solutions aimed at addressing various skin-related issues. Through its efforts, MyoScience aims to provide effective products that enhance skin health and appearance.
Viracta Therapeutics
Series B in 2012
Viracta Therapeutics, Inc. is a clinical-stage drug development company based in Cardiff, California, that specializes in precision oncology focused on virus-associated malignancies. The company utilizes a viral activation therapy platform to develop treatments for cancers linked to the Epstein-Barr Virus (EBV) and other virus-related diseases. Its lead investigational drug, nanatinostat, is being evaluated in combination with the antiviral valganciclovir as a potential oral therapy for EBV-positive lymphoma, including post-transplant lymphoproliferative disorder, plasmablastic lymphoma, and angioimmunoblastic T cell lymphoma. Viracta is also exploring the application of this approach to other EBV-associated conditions, such as nasopharyngeal carcinoma and gastric carcinoma. Founded in 2007 and rebranded from HemaQuest Pharmaceuticals in 2015, Viracta Therapeutics is actively conducting multiple clinical trials to advance its therapeutic candidates.
Pulmonx
Private Equity Round in 2012
Pulmonx Corporation is a medical technology company specializing in minimally invasive solutions for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Its primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema, as well as the Chartis Pulmonary Assessment System, which assesses collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography data to identify suitable treatment areas. Pulmonx aims to improve the quality of life for patients who remain symptomatic despite medical management and may not be candidates for surgical interventions. The company has received FDA pre-market approval for the Zephyr Valve and has established a global presence, serving markets in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. Founded in 1995 and headquartered in Redwood City, California, Pulmonx has become a leader in interventional procedures for COPD, supported by extensive clinical evidence demonstrating the effectiveness of its technologies.
iScience Interventional
Venture Round in 2012
iScience Interventional specializes in the discovery and development of microcatheter and imaging technologies aimed at enhancing ophthalmic care. The company focuses on a novel approach termed Interventional Ophthalmology, which involves microcatheter-based therapies that allow ophthalmologists to access various anatomical structures within the eye. These technologies facilitate the aspiration of ocular fluids and the delivery of sterile ophthalmic solutions, enabling targeted treatment for a range of ocular diseases. Additionally, iScience Interventional provides medical devices specifically designed for canaloplasty procedures, further contributing to advancements in the management of eye conditions.
Simpirica Spine
Series C in 2011
Simprica Spine is a stabilization system designed to stabilize the spine in flexion and helps patients rehabilitate better.
Spinal Modulation
Series D in 2011
Spinal Modulation, Inc., based in Menlo Park, California, specializes in the research and development of medical devices aimed at treating chronic pain. With a significant portion of the adult population affected by severe chronic pain and limited treatment options available, the company addresses this critical healthcare challenge through its Axium Neurostimulator System. This next-generation intraspinal neuromodulation therapy specifically targets the dorsal root ganglion (DRG) to deliver electrical pulses that disrupt pain signals before they reach the brain. The system has demonstrated effectiveness in managing chronic intractable leg pain and other complex pain areas, such as the back and foot, providing a tailored approach for pain relief. By allowing adjustments to focus on either broad or specific pain areas, Spinal Modulation's technology aims to enhance patient comfort and reduce the adverse effects commonly associated with traditional spinal cord stimulators.
WaveTec Vision
Series D in 2011
WaveTec Vision, founded in 1997 and located in Aliso Viejo, California, specializes in advanced wavefront measurement technology for cataract surgery. The company's proprietary intraoperative aberrometer system, ORange, allows surgeons to measure the eye and enhance surgical outcomes in real-time. By facilitating the convergence of refractive and cataract surgery, WaveTec Vision aims to improve the overall efficacy and precision of these procedures, ultimately benefiting patient care and satisfaction.
Benvenue Medical
Series C in 2011
Benvenue Medical, Inc. is a company specializing in the design, manufacture, and marketing of minimally invasive expandable implant systems for the treatment of spinal disorders, particularly vertebral compression fractures and degenerative disc diseases. Its key products include the Kiva treatment system, which addresses spinal fractures in the thoracic and lumbar regions, and the Blazer – C system, designed for pathological vertebral compression fractures. Additionally, the company offers the Luna 3D expandable interbody fusion system, suitable for various surgical approaches. Headquartered in Santa Clara, California, Benvenue Medical serves customers across the United States, Canada, Belgium, France, and Germany. Founded in 2004, the company is committed to providing innovative solutions that enhance patient outcomes and restore spinal alignment.
Astute Medical
Series B in 2011
Astute Medical, Inc. is a life science tools company specializing in the discovery and development of protein biomarkers for rapid diagnosis and risk assessment of acute medical conditions. Founded in 2007 and based in San Diego, California, with a location in Paris, France, the company focuses on validating prognostic biomarkers related to conditions such as abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury, and sepsis. Its primary product, NephroCheck, is a single-use cartridge designed to detect biomarkers of acute kidney injury, while the Astute140 meter converts the fluorescent signals from the NephroCheck cartridge into a single numerical result. Astute Medical's products are marketed in the United States and Europe and aim to enhance clinical decision-making and patient outcomes. As of April 2018, Astute Medical operates as a subsidiary of bioMérieux S.A.
Tria Beauty
Venture Round in 2011
TRIA Beauty, Inc. specializes in developing and selling light-based medical devices designed for consumer use in skincare and beauty treatments. The company's primary offerings include a hand-held diode laser device for permanent hair removal, a Skin Perfecting Blue Light device targeting acne-causing bacteria, a Skin Rejuvenating Laser for anti-aging, and an Age-Defying Eye Wrinkle Correcting Laser aimed at reducing fine lines around the eyes. These products leverage advanced light technology, typically used in professional dermatological treatments, allowing users to achieve salon-quality results at home. TRIA Beauty markets its products through its e-commerce platform and various indirect sales channels, including television, retail locations, and physician offices. Founded in 2003 and headquartered in Dublin, California, TRIA Beauty serves customers across multiple countries, including the United States, Japan, and several European nations. The company previously operated under the name SpectraGenics, Inc. before rebranding in 2008.
EBR Systems
Series D in 2011
EBR Systems, Inc. is focused on developing innovative implantable devices for cardiac rhythm management, specifically aimed at treating patients with heart failure and cardiac arrhythmias. The company's flagship product, the Wireless Cardiac Stimulation of the Left Ventricle System, utilizes proprietary wireless technology to provide endocardial pacing for cardiac resynchronization therapy. This approach enhances the heart's pumping efficiency by synchronizing the contractions of the left and right ventricles. Founded in 2003 and headquartered in Sunnyvale, California, EBR Systems is committed to advancing therapeutic options for patients suffering from cardiac rhythm diseases through its novel technologies.
Spiracur
Series C in 2011
Spiracur Inc. is a privately held medical device company established in 2007 through the Stanford Biodesign Innovation Program. The company specializes in developing innovative wound healing technologies, focusing on the treatment needs of diabetic patients. Its flagship product, the SNaP Wound Care System, addresses the limitations of traditional negative pressure wound therapies by offering a portable and user-friendly solution. This system is designed to promote healing in chronic wounds, particularly those that are difficult to treat, allowing patients to recover more quickly and effectively. Spiracur is dedicated to creating patient-centric products that enhance the wound care experience for both patients and clinicians.
EndoGastric Solutions
Series F in 2010
EndoGastric Solutions, Inc. is a medical device company specializing in innovative surgical technologies aimed at treating gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, the company develops and manufactures natural orifice surgical products. Its flagship technology, EsophyX, facilitates transoral reconstructive surgery, while the EsophyX Z device is specifically designed for the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions offers SerosaFuse Fasteners, a non-resorbable polypropylene product that provides strength comparable to traditional sutures. The company also supports surgeons through training courses and a range of consultative services, including pre-authorization and medical review.
Astute Medical
Series B in 2010
Astute Medical, Inc. is a life science tools company specializing in the discovery and development of protein biomarkers for rapid diagnosis and risk assessment of acute medical conditions. Founded in 2007 and based in San Diego, California, with a location in Paris, France, the company focuses on validating prognostic biomarkers related to conditions such as abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury, and sepsis. Its primary product, NephroCheck, is a single-use cartridge designed to detect biomarkers of acute kidney injury, while the Astute140 meter converts the fluorescent signals from the NephroCheck cartridge into a single numerical result. Astute Medical's products are marketed in the United States and Europe and aim to enhance clinical decision-making and patient outcomes. As of April 2018, Astute Medical operates as a subsidiary of bioMérieux S.A.
TearScience
Series C in 2010
TearScience, Inc. is a medical device company based in Morrisville, North Carolina, focused on the identification, diagnosis, and treatment of Meibomian Gland Dysfunction (MGD), which is the primary cause of evaporative dry eye affecting over 100 million people globally. The company has developed innovative devices such as the LipiFlow Activator, which delivers automated therapeutic energies to meibomian glands while safeguarding the eye's delicate structures, and LipiScan, an imaging system that allows eye care professionals to assess gland health. MGD is often under-recognized and contributes significantly to dry eye symptoms such as irritation, dryness, and visual disturbances. By providing a comprehensive in-office system, TearScience enables eye care professionals to effectively address the root causes of evaporative dry eye, ultimately improving patient outcomes. The company, originally known as Kolis Scientific, Inc., was rebranded in 2005 and is now a subsidiary of Johnson & Johnson Surgical Vision, Inc.
Viracta Therapeutics
Series B in 2010
Viracta Therapeutics, Inc. is a clinical-stage drug development company based in Cardiff, California, that specializes in precision oncology focused on virus-associated malignancies. The company utilizes a viral activation therapy platform to develop treatments for cancers linked to the Epstein-Barr Virus (EBV) and other virus-related diseases. Its lead investigational drug, nanatinostat, is being evaluated in combination with the antiviral valganciclovir as a potential oral therapy for EBV-positive lymphoma, including post-transplant lymphoproliferative disorder, plasmablastic lymphoma, and angioimmunoblastic T cell lymphoma. Viracta is also exploring the application of this approach to other EBV-associated conditions, such as nasopharyngeal carcinoma and gastric carcinoma. Founded in 2007 and rebranded from HemaQuest Pharmaceuticals in 2015, Viracta Therapeutics is actively conducting multiple clinical trials to advance its therapeutic candidates.
Articulinx
Series B in 2010
Articulinx, Inc. is a medical device company based in Cupertino, California, specializing in the manufacture of implants and devices for the treatment of hand osteoarthritis. Founded in 2007, the company focuses on providing minimally-invasive solutions that restore joint mobility and alleviate joint pain, thereby reducing the need for surgeries. Its products cater to the orthopedic, extremities, and small joints markets in the United States, aiming to improve patient outcomes and enhance quality of life for those suffering from hand osteoarthritis.
Pulmonx
Series C in 2010
Pulmonx Corporation is a medical technology company specializing in minimally invasive solutions for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Its primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema, as well as the Chartis Pulmonary Assessment System, which assesses collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography data to identify suitable treatment areas. Pulmonx aims to improve the quality of life for patients who remain symptomatic despite medical management and may not be candidates for surgical interventions. The company has received FDA pre-market approval for the Zephyr Valve and has established a global presence, serving markets in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. Founded in 1995 and headquartered in Redwood City, California, Pulmonx has become a leader in interventional procedures for COPD, supported by extensive clinical evidence demonstrating the effectiveness of its technologies.
EndoGastric Solutions
Series E in 2010
EndoGastric Solutions, Inc. is a medical device company specializing in innovative surgical technologies aimed at treating gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, the company develops and manufactures natural orifice surgical products. Its flagship technology, EsophyX, facilitates transoral reconstructive surgery, while the EsophyX Z device is specifically designed for the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions offers SerosaFuse Fasteners, a non-resorbable polypropylene product that provides strength comparable to traditional sutures. The company also supports surgeons through training courses and a range of consultative services, including pre-authorization and medical review.
EBR Systems
Venture Round in 2009
EBR Systems, Inc. is focused on developing innovative implantable devices for cardiac rhythm management, specifically aimed at treating patients with heart failure and cardiac arrhythmias. The company's flagship product, the Wireless Cardiac Stimulation of the Left Ventricle System, utilizes proprietary wireless technology to provide endocardial pacing for cardiac resynchronization therapy. This approach enhances the heart's pumping efficiency by synchronizing the contractions of the left and right ventricles. Founded in 2003 and headquartered in Sunnyvale, California, EBR Systems is committed to advancing therapeutic options for patients suffering from cardiac rhythm diseases through its novel technologies.
Spinal Modulation
Series C in 2009
Spinal Modulation, Inc., based in Menlo Park, California, specializes in the research and development of medical devices aimed at treating chronic pain. With a significant portion of the adult population affected by severe chronic pain and limited treatment options available, the company addresses this critical healthcare challenge through its Axium Neurostimulator System. This next-generation intraspinal neuromodulation therapy specifically targets the dorsal root ganglion (DRG) to deliver electrical pulses that disrupt pain signals before they reach the brain. The system has demonstrated effectiveness in managing chronic intractable leg pain and other complex pain areas, such as the back and foot, providing a tailored approach for pain relief. By allowing adjustments to focus on either broad or specific pain areas, Spinal Modulation's technology aims to enhance patient comfort and reduce the adverse effects commonly associated with traditional spinal cord stimulators.
EndoGastric Solutions
Venture Round in 2009
EndoGastric Solutions, Inc. is a medical device company specializing in innovative surgical technologies aimed at treating gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, the company develops and manufactures natural orifice surgical products. Its flagship technology, EsophyX, facilitates transoral reconstructive surgery, while the EsophyX Z device is specifically designed for the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions offers SerosaFuse Fasteners, a non-resorbable polypropylene product that provides strength comparable to traditional sutures. The company also supports surgeons through training courses and a range of consultative services, including pre-authorization and medical review.
Spinal Kinetics
Debt Financing in 2009
Spinal Kinetics LLC is a medical device company based in Sunnyvale, California, dedicated to developing non-fusion motion preservation systems for treating degenerative diseases of the spine. Founded in 2003, the company offers two primary products: the M6-C artificial cervical disc and the M6-L artificial lumbar disc, both designed to replicate the anatomical and biomechanical characteristics of natural intervertebral discs. These innovations provide options for artificial disc replacement in the cervical and lumbar regions. Spinal Kinetics collaborates with spine surgeons to ensure that its products meet clinical needs and are sold through a network of distributors across various countries, including Australia, Germany, the United Kingdom, and the United Arab Emirates. The company operates as a subsidiary of Orthofix Medical Inc.
EndoGastric Solutions
Venture Round in 2009
EndoGastric Solutions, Inc. is a medical device company specializing in innovative surgical technologies aimed at treating gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, the company develops and manufactures natural orifice surgical products. Its flagship technology, EsophyX, facilitates transoral reconstructive surgery, while the EsophyX Z device is specifically designed for the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions offers SerosaFuse Fasteners, a non-resorbable polypropylene product that provides strength comparable to traditional sutures. The company also supports surgeons through training courses and a range of consultative services, including pre-authorization and medical review.
Spiracur
Series B in 2009
Spiracur Inc. is a privately held medical device company established in 2007 through the Stanford Biodesign Innovation Program. The company specializes in developing innovative wound healing technologies, focusing on the treatment needs of diabetic patients. Its flagship product, the SNaP Wound Care System, addresses the limitations of traditional negative pressure wound therapies by offering a portable and user-friendly solution. This system is designed to promote healing in chronic wounds, particularly those that are difficult to treat, allowing patients to recover more quickly and effectively. Spiracur is dedicated to creating patient-centric products that enhance the wound care experience for both patients and clinicians.
Facet Solutions
Debt Financing in 2009
Facet Solutions, established in 2003 and headquartered in Hopkinton, Massachusetts, specializes in developing surgical devices for treating degenerative spinal disorders. The company's primary product is an anatomic facet joint reconstruction device, designed to provide patients with lumbar spinal stenosis and facet degeneration a motion preservation alternative to lumbar spinal fusion.
PhotoThera
Series D in 2009
PhotoThera is currently hiring for the following positions: Sr. Software Engineer Mechanical Engineer Configuration Management Engineer Sr. Electrical Engineer Send your resume and cover letter to ktitano@photothera.com, or go to www.photothera.com for further information. Specialties laser, medical device, eschemic, stroke, infrared
iScience Interventional
Series F in 2009
iScience Interventional specializes in the discovery and development of microcatheter and imaging technologies aimed at enhancing ophthalmic care. The company focuses on a novel approach termed Interventional Ophthalmology, which involves microcatheter-based therapies that allow ophthalmologists to access various anatomical structures within the eye. These technologies facilitate the aspiration of ocular fluids and the delivery of sterile ophthalmic solutions, enabling targeted treatment for a range of ocular diseases. Additionally, iScience Interventional provides medical devices specifically designed for canaloplasty procedures, further contributing to advancements in the management of eye conditions.
SynergEyes
Series C in 2009
SynergEyes, Inc. is a technology-driven company specializing in the manufacture and sale of contact lenses for eye care professionals. Founded in 2001 and based in Carlsbad, California, SynergEyes focuses on hybrid contact lenses that combine the clarity of rigid gas permeable lenses with the comfort of soft lenses. Their product offerings cater to various eye conditions, including astigmatism, presbyopia, myopia, hyperopia, and keratoconus. By utilizing advanced high-Dk materials and vision-optimized designs, SynergEyes aims to enhance vision and quality of life for its patients. The company's products are distributed in the United States and internationally, addressing a recognized need for innovative lens solutions in the eye care industry.
WaveTec Vision
Series C in 2009
WaveTec Vision, founded in 1997 and located in Aliso Viejo, California, specializes in advanced wavefront measurement technology for cataract surgery. The company's proprietary intraoperative aberrometer system, ORange, allows surgeons to measure the eye and enhance surgical outcomes in real-time. By facilitating the convergence of refractive and cataract surgery, WaveTec Vision aims to improve the overall efficacy and precision of these procedures, ultimately benefiting patient care and satisfaction.
OncoMed Pharmaceuticals
Series B in 2008
OncoMed Pharmaceuticals is a clinical-stage biopharmaceutical company based in Redwood City, California, specializing in the discovery and development of innovative therapeutics aimed at addressing the biological mechanisms that drive cancer growth, resistance, recurrence, and metastasis. The company is advancing several therapeutic candidates, including Navicixizumab, a bispecific monoclonal antibody targeting Delta-like ligand 4 and vascular endothelial growth factor, which has completed early-phase clinical trials for various solid tumors. Another key candidate, Etigilimab, is an anti-TIGIT monoclonal antibody currently undergoing Phase Ia/b clinical trials for advanced or metastatic solid tumors. OncoMed is also engaged in strategic partnerships aimed at the development of novel small molecule therapeutics and biologics targeting cancer stem cells and the Wnt signaling pathway. Founded in 2004, OncoMed Pharmaceuticals operates as a subsidiary of Mereo BioPharma Group plc.
InSound Medical
Series E in 2008
InSound Medical, Inc. is a privately held company located in Newark, California, specializing in the development and manufacture of advanced hearing solutions. The company is backed by prominent investors such as Johnson & Johnson, DeNovo Ventures, CMEA Ventures, and Psilos Group Managers, LLC. InSound Medical's flagship product is Lyric, an innovative invisible extended wear hearing device designed to provide users with a discreet and effective hearing solution.
Sierra Surgical
Series B in 2008
Sierra Surgical Technologies develops minimally invasive surgical systems. The company develops female sterilization technology. Sierra Surgical Technologies, Inc. is based in Palo Alto, California.
MyoScience
Series B in 2008
MyoScience Inc., founded in 2005 and based in Redwood City, California, focuses on the development and commercialization of innovative dermatological products. The company leverages advanced technology to create solutions aimed at addressing various skin-related issues. Through its efforts, MyoScience aims to provide effective products that enhance skin health and appearance.
EBR Systems
Series C in 2008
EBR Systems, Inc. is focused on developing innovative implantable devices for cardiac rhythm management, specifically aimed at treating patients with heart failure and cardiac arrhythmias. The company's flagship product, the Wireless Cardiac Stimulation of the Left Ventricle System, utilizes proprietary wireless technology to provide endocardial pacing for cardiac resynchronization therapy. This approach enhances the heart's pumping efficiency by synchronizing the contractions of the left and right ventricles. Founded in 2003 and headquartered in Sunnyvale, California, EBR Systems is committed to advancing therapeutic options for patients suffering from cardiac rhythm diseases through its novel technologies.
Astute Medical
Series A in 2008
Astute Medical, Inc. is a life science tools company specializing in the discovery and development of protein biomarkers for rapid diagnosis and risk assessment of acute medical conditions. Founded in 2007 and based in San Diego, California, with a location in Paris, France, the company focuses on validating prognostic biomarkers related to conditions such as abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury, and sepsis. Its primary product, NephroCheck, is a single-use cartridge designed to detect biomarkers of acute kidney injury, while the Astute140 meter converts the fluorescent signals from the NephroCheck cartridge into a single numerical result. Astute Medical's products are marketed in the United States and Europe and aim to enhance clinical decision-making and patient outcomes. As of April 2018, Astute Medical operates as a subsidiary of bioMérieux S.A.
CardioMind
Venture Round in 2008
CardioMind, Inc. Inc manufactures therapeutic devices for cardiovascular diseases. The company also offers stent delivery systems, which are designed for use in lesion applications, as well as for the treatment of coronary and peripheral artery diseases. In addition, it provides invasive endovascular medical devices for treating neurological and cardiovascular diseases. The company was founded in 2003 and is based in Sunnyvale, California.
InSound Medical
Series E in 2008
InSound Medical, Inc. is a privately held company located in Newark, California, specializing in the development and manufacture of advanced hearing solutions. The company is backed by prominent investors such as Johnson & Johnson, DeNovo Ventures, CMEA Ventures, and Psilos Group Managers, LLC. InSound Medical's flagship product is Lyric, an innovative invisible extended wear hearing device designed to provide users with a discreet and effective hearing solution.
Avedro
Series A in 2008
Avedro, Inc. is a medical device and pharmaceutical company specializing in the treatment of corneal disorders, particularly corneal ectatic conditions and refractive errors. The company has developed the Avedro Corneal Remodeling platform, which includes the KXL and Mosaic systems that utilize ultraviolet A (UVA) light, alongside a range of single-use riboflavin drug formulations. These technologies are primarily aimed at treating progressive keratoconus and corneal ectasia following refractive surgery. Avedro also focuses on advancing the science of Thermo-biomechanics, exemplified by its Keraflex procedure, a non-invasive method for corneal reshaping that preserves the cornea's biomechanical integrity. The company's products are marketed to ophthalmologists, hospitals, and ambulatory surgery centers in the United States and through international distributors. Avedro, originally established as ThermalVision, Inc. in 2002, is headquartered in Waltham, Massachusetts, and operates as a subsidiary of Glaukos Corporation.
Benvenue Medical
Series B in 2008
Benvenue Medical, Inc. is a company specializing in the design, manufacture, and marketing of minimally invasive expandable implant systems for the treatment of spinal disorders, particularly vertebral compression fractures and degenerative disc diseases. Its key products include the Kiva treatment system, which addresses spinal fractures in the thoracic and lumbar regions, and the Blazer – C system, designed for pathological vertebral compression fractures. Additionally, the company offers the Luna 3D expandable interbody fusion system, suitable for various surgical approaches. Headquartered in Santa Clara, California, Benvenue Medical serves customers across the United States, Canada, Belgium, France, and Germany. Founded in 2004, the company is committed to providing innovative solutions that enhance patient outcomes and restore spinal alignment.
POINT Biomedical
Private Equity Round in 2008
POINT Biomedical is a privately held pharmaceutical company, founded to pursue technologies related to imaging and drug delivery. POINT's core technology is based upon an ultrasonically responsive two-layer, biodegradable microsphere or biSphereâ„¢. One of the most important features of this technology is the ability to noninvasively trigger the biSpheres to release their contents at sites within the body using externally generated pulses of ultrasound. From this basic platform, POINT is developing a pipeline of products that leverage the unique properties of the biSphere technology in the areas of imaging and therapeutics. POINT has initially focused development of this platform on the assessment of tissue specific blood flow. The lead product, CARDIOsphereâ„¢, is a pharmaceutical agent that will enable cardiologists to perform myocardial perfusion imaging studies in the office setting using ultrasound rather than more expensive and cumbersome nuclear (or radioisotope) techniques
Axogen
Post in 2007
AxoGen, Inc. is a company focused on developing and commercializing innovative solutions for the repair and regeneration of peripheral nerve injuries. Based in Alachua, Florida, and founded in 2002, AxoGen offers a range of products designed for effective surgical procedures, including the AVANCE Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. Additionally, it provides the Axotouch Two-Point Discriminator, a device used to assess the innervation density of skin. AxoGen's offerings are aimed at surgeons and healthcare providers, ensuring clinically and economically effective solutions for nerve repair. The company also has a strategic partnership with the American Tissue Services Foundation for tissue recovery and distributes its products across the United States and several international markets, including Canada, Germany, the United Kingdom, Spain, and South Korea.
Viracta Therapeutics
Series A in 2007
Viracta Therapeutics, Inc. is a clinical-stage drug development company based in Cardiff, California, that specializes in precision oncology focused on virus-associated malignancies. The company utilizes a viral activation therapy platform to develop treatments for cancers linked to the Epstein-Barr Virus (EBV) and other virus-related diseases. Its lead investigational drug, nanatinostat, is being evaluated in combination with the antiviral valganciclovir as a potential oral therapy for EBV-positive lymphoma, including post-transplant lymphoproliferative disorder, plasmablastic lymphoma, and angioimmunoblastic T cell lymphoma. Viracta is also exploring the application of this approach to other EBV-associated conditions, such as nasopharyngeal carcinoma and gastric carcinoma. Founded in 2007 and rebranded from HemaQuest Pharmaceuticals in 2015, Viracta Therapeutics is actively conducting multiple clinical trials to advance its therapeutic candidates.
Vitreoretinal Technologies
Series A in 2007
Vitreoretinal Technologies, Inc., an ophthalmic biopharmaceutical company, engages in the development and commercialization of therapeutic compounds for the treatment of ophthalmic diseases. The company focuses on vitreoretinal ophthalmic diseases and complications related to ophthalmic surgery. Its products include Vitreosolve, a drug used for the treatment of diabetic retinopathy, as well as to liquefy the vitreous gel prior to vitrectomy surgery; and Neurosolve, a compound used for glaucomatous optic nerve damage progression prevention, dry age related macular degeneration progression, and retinitis pigmentosa treatment.
EndoGastric Solutions
Series D in 2007
EndoGastric Solutions, Inc. is a medical device company specializing in innovative surgical technologies aimed at treating gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, the company develops and manufactures natural orifice surgical products. Its flagship technology, EsophyX, facilitates transoral reconstructive surgery, while the EsophyX Z device is specifically designed for the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions offers SerosaFuse Fasteners, a non-resorbable polypropylene product that provides strength comparable to traditional sutures. The company also supports surgeons through training courses and a range of consultative services, including pre-authorization and medical review.
Sierra Surgical
Series A in 2007
Sierra Surgical Technologies develops minimally invasive surgical systems. The company develops female sterilization technology. Sierra Surgical Technologies, Inc. is based in Palo Alto, California.
CardioMind
Series C in 2007
CardioMind, Inc. Inc manufactures therapeutic devices for cardiovascular diseases. The company also offers stent delivery systems, which are designed for use in lesion applications, as well as for the treatment of coronary and peripheral artery diseases. In addition, it provides invasive endovascular medical devices for treating neurological and cardiovascular diseases. The company was founded in 2003 and is based in Sunnyvale, California.
Paracor Medical
Series D in 2007
Paracor Medical is a medical device company established in 1999 that specializes in developing innovative, technology-driven solutions for the treatment of heart failure. The company focuses on creating alternatives to traditional open chest surgery, aiming to alleviate the burden on patients with failing heart muscles. By employing a mechanical approach, Paracor Medical seeks to enhance the effectiveness of heart failure treatment while minimizing the invasiveness of procedures.
WaveTec Vision
Series B in 2007
WaveTec Vision, founded in 1997 and located in Aliso Viejo, California, specializes in advanced wavefront measurement technology for cataract surgery. The company's proprietary intraoperative aberrometer system, ORange, allows surgeons to measure the eye and enhance surgical outcomes in real-time. By facilitating the convergence of refractive and cataract surgery, WaveTec Vision aims to improve the overall efficacy and precision of these procedures, ultimately benefiting patient care and satisfaction.
Talima Therapeutics
Series B in 2007
Talima Therapeutics is an emerging drug delivery company dedicated to the development of novel products that increase patient choice and improve quality of life. With a unique approach to therapy, we design customized drug-delivery systems that optimize the local therapeutic performance and reduce the undesired systemic side effects enabling us to address unmet needs or underserved markets. We foster a collaborative environment and strive for excellence internally and with our partners. Our lead product is currently in Phase I/II clinical testing for the treatment of onychomycosis, a fungal disease of the nails and we are in the process of planning its pivotal trials.
Tria Beauty
Series D in 2007
TRIA Beauty, Inc. specializes in developing and selling light-based medical devices designed for consumer use in skincare and beauty treatments. The company's primary offerings include a hand-held diode laser device for permanent hair removal, a Skin Perfecting Blue Light device targeting acne-causing bacteria, a Skin Rejuvenating Laser for anti-aging, and an Age-Defying Eye Wrinkle Correcting Laser aimed at reducing fine lines around the eyes. These products leverage advanced light technology, typically used in professional dermatological treatments, allowing users to achieve salon-quality results at home. TRIA Beauty markets its products through its e-commerce platform and various indirect sales channels, including television, retail locations, and physician offices. Founded in 2003 and headquartered in Dublin, California, TRIA Beauty serves customers across multiple countries, including the United States, Japan, and several European nations. The company previously operated under the name SpectraGenics, Inc. before rebranding in 2008.
Pulmonx
Series B in 2007
Pulmonx Corporation is a medical technology company specializing in minimally invasive solutions for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Its primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema, as well as the Chartis Pulmonary Assessment System, which assesses collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography data to identify suitable treatment areas. Pulmonx aims to improve the quality of life for patients who remain symptomatic despite medical management and may not be candidates for surgical interventions. The company has received FDA pre-market approval for the Zephyr Valve and has established a global presence, serving markets in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. Founded in 1995 and headquartered in Redwood City, California, Pulmonx has become a leader in interventional procedures for COPD, supported by extensive clinical evidence demonstrating the effectiveness of its technologies.
TearScience
Series B in 2007
TearScience, Inc. is a medical device company based in Morrisville, North Carolina, focused on the identification, diagnosis, and treatment of Meibomian Gland Dysfunction (MGD), which is the primary cause of evaporative dry eye affecting over 100 million people globally. The company has developed innovative devices such as the LipiFlow Activator, which delivers automated therapeutic energies to meibomian glands while safeguarding the eye's delicate structures, and LipiScan, an imaging system that allows eye care professionals to assess gland health. MGD is often under-recognized and contributes significantly to dry eye symptoms such as irritation, dryness, and visual disturbances. By providing a comprehensive in-office system, TearScience enables eye care professionals to effectively address the root causes of evaporative dry eye, ultimately improving patient outcomes. The company, originally known as Kolis Scientific, Inc., was rebranded in 2005 and is now a subsidiary of Johnson & Johnson Surgical Vision, Inc.
Ovalis
Series B in 2007
Ovalis is a biotechnology company that develops catheter-based medical devices for the repair of cardiovascular defects.The company is based in Mountain View, California.
InSound Medical
Series E in 2006
InSound Medical, Inc. is a privately held company located in Newark, California, specializing in the development and manufacture of advanced hearing solutions. The company is backed by prominent investors such as Johnson & Johnson, DeNovo Ventures, CMEA Ventures, and Psilos Group Managers, LLC. InSound Medical's flagship product is Lyric, an innovative invisible extended wear hearing device designed to provide users with a discreet and effective hearing solution.
SynergEyes
Series B in 2006
SynergEyes, Inc. is a technology-driven company specializing in the manufacture and sale of contact lenses for eye care professionals. Founded in 2001 and based in Carlsbad, California, SynergEyes focuses on hybrid contact lenses that combine the clarity of rigid gas permeable lenses with the comfort of soft lenses. Their product offerings cater to various eye conditions, including astigmatism, presbyopia, myopia, hyperopia, and keratoconus. By utilizing advanced high-Dk materials and vision-optimized designs, SynergEyes aims to enhance vision and quality of life for its patients. The company's products are distributed in the United States and internationally, addressing a recognized need for innovative lens solutions in the eye care industry.
PhotoThera
Series C in 2006
PhotoThera is currently hiring for the following positions: Sr. Software Engineer Mechanical Engineer Configuration Management Engineer Sr. Electrical Engineer Send your resume and cover letter to ktitano@photothera.com, or go to www.photothera.com for further information. Specialties laser, medical device, eschemic, stroke, infrared
Cartilix
Series B in 2006
Cartilix develops and commercializes biomaterials to repair damaged tissues in articular joints and other applications. It focuses on a technology for cartilage filling in regenerative medicine. The company was founded in 2004 and is based in Foster City, California.
Spinal Modulation
Series A in 2006
Spinal Modulation, Inc., based in Menlo Park, California, specializes in the research and development of medical devices aimed at treating chronic pain. With a significant portion of the adult population affected by severe chronic pain and limited treatment options available, the company addresses this critical healthcare challenge through its Axium Neurostimulator System. This next-generation intraspinal neuromodulation therapy specifically targets the dorsal root ganglion (DRG) to deliver electrical pulses that disrupt pain signals before they reach the brain. The system has demonstrated effectiveness in managing chronic intractable leg pain and other complex pain areas, such as the back and foot, providing a tailored approach for pain relief. By allowing adjustments to focus on either broad or specific pain areas, Spinal Modulation's technology aims to enhance patient comfort and reduce the adverse effects commonly associated with traditional spinal cord stimulators.
Spinal Kinetics
Series B in 2006
Spinal Kinetics LLC is a medical device company based in Sunnyvale, California, dedicated to developing non-fusion motion preservation systems for treating degenerative diseases of the spine. Founded in 2003, the company offers two primary products: the M6-C artificial cervical disc and the M6-L artificial lumbar disc, both designed to replicate the anatomical and biomechanical characteristics of natural intervertebral discs. These innovations provide options for artificial disc replacement in the cervical and lumbar regions. Spinal Kinetics collaborates with spine surgeons to ensure that its products meet clinical needs and are sold through a network of distributors across various countries, including Australia, Germany, the United Kingdom, and the United Arab Emirates. The company operates as a subsidiary of Orthofix Medical Inc.
Facet Solutions
Series B in 2005
Facet Solutions, established in 2003 and headquartered in Hopkinton, Massachusetts, specializes in developing surgical devices for treating degenerative spinal disorders. The company's primary product is an anatomic facet joint reconstruction device, designed to provide patients with lumbar spinal stenosis and facet degeneration a motion preservation alternative to lumbar spinal fusion.
FlowMedica
Series D in 2005
FlowMedica is a medical device company that specializes in intravascular systems for Targeted Renal Therapy, addressing renal conditions linked to cardiovascular disease, cancer, and surgical procedures. The company's flagship products include the Benephit CV Infusion System, which allows physicians to deliver therapeutic agents directly into the renal arteries via an infusion catheter, while facilitating simultaneous coronary procedures through a single access site in the femoral artery. Additionally, FlowMedica offers the Benephit XTMini Infusion System, designed for bilateral infusion to the kidneys, particularly beneficial for patients with smaller vascular anatomies. By providing a targeted approach to renal therapy, FlowMedica's devices serve as an effective alternative to traditional systemic intravenous infusion methods, enabling precise delivery in various clinical scenarios.
Ovalis
Series A in 2005
Ovalis is a biotechnology company that develops catheter-based medical devices for the repair of cardiovascular defects.The company is based in Mountain View, California.
PhotoThera
Series B in 2005
PhotoThera is currently hiring for the following positions: Sr. Software Engineer Mechanical Engineer Configuration Management Engineer Sr. Electrical Engineer Send your resume and cover letter to ktitano@photothera.com, or go to www.photothera.com for further information. Specialties laser, medical device, eschemic, stroke, infrared
EBR Systems
Series B in 2005
EBR Systems, Inc. is focused on developing innovative implantable devices for cardiac rhythm management, specifically aimed at treating patients with heart failure and cardiac arrhythmias. The company's flagship product, the Wireless Cardiac Stimulation of the Left Ventricle System, utilizes proprietary wireless technology to provide endocardial pacing for cardiac resynchronization therapy. This approach enhances the heart's pumping efficiency by synchronizing the contractions of the left and right ventricles. Founded in 2003 and headquartered in Sunnyvale, California, EBR Systems is committed to advancing therapeutic options for patients suffering from cardiac rhythm diseases through its novel technologies.
Talima Therapeutics
Series A in 2005
Talima Therapeutics is an emerging drug delivery company dedicated to the development of novel products that increase patient choice and improve quality of life. With a unique approach to therapy, we design customized drug-delivery systems that optimize the local therapeutic performance and reduce the undesired systemic side effects enabling us to address unmet needs or underserved markets. We foster a collaborative environment and strive for excellence internally and with our partners. Our lead product is currently in Phase I/II clinical testing for the treatment of onychomycosis, a fungal disease of the nails and we are in the process of planning its pivotal trials.
iScience Surgical
Series C in 2005
iScience Surgical, Inc. is a privately-held company founded in 1999. It is developing high resolution imaging systems and microsurgical instruments for the treatment of glaucoma. The Company's products are designed to complement existing glaucoma surgical techniques and serve as a platform for a new generation of minimally invasive procedures. Glaucoma is a sight threatening circulatory disorder of the eye that affects approximately 4.2 million Americans and 69 million people worldwide. More than $2 billion is spent annually on glaucoma medications and treatments worldwide, the majority of which are unable to restore the eye's natural drainage process.
Paracor Medical
Series C in 2004
Paracor Medical is a medical device company established in 1999 that specializes in developing innovative, technology-driven solutions for the treatment of heart failure. The company focuses on creating alternatives to traditional open chest surgery, aiming to alleviate the burden on patients with failing heart muscles. By employing a mechanical approach, Paracor Medical seeks to enhance the effectiveness of heart failure treatment while minimizing the invasiveness of procedures.
EBR Systems
Series A in 2004
EBR Systems, Inc. is focused on developing innovative implantable devices for cardiac rhythm management, specifically aimed at treating patients with heart failure and cardiac arrhythmias. The company's flagship product, the Wireless Cardiac Stimulation of the Left Ventricle System, utilizes proprietary wireless technology to provide endocardial pacing for cardiac resynchronization therapy. This approach enhances the heart's pumping efficiency by synchronizing the contractions of the left and right ventricles. Founded in 2003 and headquartered in Sunnyvale, California, EBR Systems is committed to advancing therapeutic options for patients suffering from cardiac rhythm diseases through its novel technologies.
Spinal Kinetics
Series A in 2004
Spinal Kinetics LLC is a medical device company based in Sunnyvale, California, dedicated to developing non-fusion motion preservation systems for treating degenerative diseases of the spine. Founded in 2003, the company offers two primary products: the M6-C artificial cervical disc and the M6-L artificial lumbar disc, both designed to replicate the anatomical and biomechanical characteristics of natural intervertebral discs. These innovations provide options for artificial disc replacement in the cervical and lumbar regions. Spinal Kinetics collaborates with spine surgeons to ensure that its products meet clinical needs and are sold through a network of distributors across various countries, including Australia, Germany, the United Kingdom, and the United Arab Emirates. The company operates as a subsidiary of Orthofix Medical Inc.
InSound Medical
Series D in 2004
InSound Medical, Inc. is a privately held company located in Newark, California, specializing in the development and manufacture of advanced hearing solutions. The company is backed by prominent investors such as Johnson & Johnson, DeNovo Ventures, CMEA Ventures, and Psilos Group Managers, LLC. InSound Medical's flagship product is Lyric, an innovative invisible extended wear hearing device designed to provide users with a discreet and effective hearing solution.
Bacchus Vascular
Series D in 2003
Bacchus Vascular, Inc. is a medical device company based in Santa Clara, California, specializing in the treatment of occlusive vascular disease. Founded in 1999, it develops innovative solutions for interventional radiologists and vascular surgeons in the United States. The company's flagship product, the TRELLIS-8 Peripheral Infusion System, is an isolated thrombolysis catheter designed to facilitate the targeted delivery of clot-dissolving drugs for the treatment of deep vein thrombosis and arterial occlusions. Additionally, Bacchus Vascular focuses on procedures for the percutaneous removal of blood clots from dialysis and peripheral grafts, as well as native arteries and veins, enhancing patient care in the field of vascular interventions.
iScience Interventional
Series C in 2003
iScience Interventional specializes in the discovery and development of microcatheter and imaging technologies aimed at enhancing ophthalmic care. The company focuses on a novel approach termed Interventional Ophthalmology, which involves microcatheter-based therapies that allow ophthalmologists to access various anatomical structures within the eye. These technologies facilitate the aspiration of ocular fluids and the delivery of sterile ophthalmic solutions, enabling targeted treatment for a range of ocular diseases. Additionally, iScience Interventional provides medical devices specifically designed for canaloplasty procedures, further contributing to advancements in the management of eye conditions.
iScience Surgical
Series B in 2003
iScience Surgical, Inc. is a privately-held company founded in 1999. It is developing high resolution imaging systems and microsurgical instruments for the treatment of glaucoma. The Company's products are designed to complement existing glaucoma surgical techniques and serve as a platform for a new generation of minimally invasive procedures. Glaucoma is a sight threatening circulatory disorder of the eye that affects approximately 4.2 million Americans and 69 million people worldwide. More than $2 billion is spent annually on glaucoma medications and treatments worldwide, the majority of which are unable to restore the eye's natural drainage process.
Lumend
Series D in 2003
LuMend Inc. designs, develops, manufactures and markets medical devices intended to enable physicians to safely, predictably and cost effectively cross Chronic Total Occlusions (CTO) in the coronary vasculature, allowing subsequent conventional guide wire placement across target stenotic lesions. The company was founded in 1996 by two pioneering interventional cardiologists, John Simpson, PhD, MD, and Matthew Selmon, MD.
Renovis
Series B in 2002
Renovis, Inc. is a biopharmaceutical company focused on the development of drugs for neurological diseases and disorders. The company is actively working on treatments for acute ischemic stroke, neuropathic pain, and acute post-operative pain. Utilizing a range of scientific disciplines, including molecular biology, medicinal chemistry, pharmacology, drug metabolism, toxicology, and informatics, Renovis aims to identify and select small molecule drug candidates that adhere to rigorous development standards.
MicroVention Terumo
Series C in 2001
MicroVention Terumo is a medical device company specializing in catheter-based and minimally-invasive technologies for treating cerebral aneurysms and other neurovascular conditions. Founded in 1997 and headquartered in Tustin, California, the company develops a range of products, including delivery and detachment systems, access products, intraluminal devices, occlusion balloons, and flow diverters. Its notable technologies include the HydroCoil Embolic System, which utilizes platinum micro-coil technology for endovascular embolization, and the MicroPlex Coil System, designed for various aneurysm morphologies. MicroVention Terumo distributes its products through a network of specialty distributors across North America, South America, Europe, Africa, the Middle East, and Asia Pacific. The company has been operating as a subsidiary of Terumo Corporation since 2006.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.